SEC Form 4 · accession 0001144204-17-026954
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Walter V Klemp
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
May 11, 2017
Accepted (ET)
May 12, 2017 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659617
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2017 | P | 12,000 | $0.81 | A | 1,067,724 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1In addition to the shares held directly by the reporting person, the reporting person is the majority shareholder and control person of Annamed, Inc. Annamed, Inc. holds 1,425,000 shares of Issuer common stock. The Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by Annamed, Inc.